What Is Letybo?
Letybo is the newest FDA-approved neurotoxin in the United States. Made by South Korean pharmaceutical company Hugel, it received approval in January 2024 for treating moderate to severe frown lines. The generic name is letibotulinumtoxinA.
Like Botox, Dysport, Xeomin, Jeuveau, and Daxxify, Letybo is botulinum toxin type A. Same mechanism of action. It blocks nerve signals to muscles, temporarily relaxing them and smoothing wrinkles caused by repeated facial expressions.
What makes Letybo interesting isn't that it's radically different. It's that it represents Korean pharmaceutical innovation entering the American market, backed by a decade of real-world use in Asia.
Letybo at a Glance
- Generic name: LetibotulinumtoxinA
- Manufacturer: Hugel (South Korea)
- FDA approval: January 2024
- Approved indication: Glabellar lines (frown lines)
- Unit conversion: 1:1 with Botox
The Korean Connection: Why It Matters
South Korea isn't just the home of K-pop and K-drama. It's one of the world's most advanced markets for aesthetic medicine. Per capita, South Korea has more cosmetic procedures performed than almost any other country.
This intensity creates pressure for innovation. Korean pharmaceutical companies compete fiercely on quality, safety, and results. Products that succeed in Korea have been refined by one of the most demanding aesthetic markets on earth.
Korea's Aesthetic Medicine Leadership
By the Numbers
- •#1 in cosmetic procedures per capita globally
- •$10+ billion aesthetic medicine market
- •Medical tourism destination for Asia
- •Advanced regulatory standards
Hugel's Position
- •Founded 2001, over 20 years experience
- •One of Asia's largest toxin producers
- •Products in 50+ countries
- •Full aesthetic portfolio (fillers, toxins)
Letybo has been available in South Korea since 2014 under the name Botulax. Ten years of real-world use. Millions of treatments. When a product survives a decade in Korea's competitive market, it's proven something about quality and results.
The K-Beauty Effect
Korean beauty and skincare products have earned global respect for innovation and quality. Letybo represents that same philosophy applied to medical aesthetics. It's not just marketing hype: Korean companies have genuine expertise in this space.
Clinical Trial Data: What the Studies Show
Letybo's FDA approval was based on two Phase 3 clinical trials conducted in the United States. These trials compared Letybo to placebo for treating glabellar lines. The results met FDA standards.
Trial Results
- •600+ patients in US trials
- •Significant improvement vs placebo
- •Duration similar to Botox (3-4 months)
- •Comparable safety profile
Safety Profile
- •Headache: most common side effect
- •Eyelid ptosis (drooping): rare
- •Injection site reactions: mild
- •No serious adverse events reported
The FDA requires rigorous clinical evidence for approval. Letybo met the same standards as Botox, Dysport, and other approved neurotoxins. The trials demonstrated both efficacy (it works) and safety (it's well-tolerated).
Real-World Evidence from Asia
Beyond US trials, Letybo (as Botulax) has extensive real-world data:
Cost Comparison: Where Letybo Might Win
Here's where Letybo gets interesting. As a new market entrant, Hugel is positioning Letybo as a cost-competitive alternative to established brands. Early pricing suggests savings of 10-20%.
Botox Pricing
Letybo Pricing
These numbers are estimates and will vary by provider and location. During the launch period, many providers are offering promotional pricing to encourage patients to try Letybo. If you're price-sensitive, it's worth asking about current offers.
Potential Annual Savings
For someone getting treatments 3 times per year:
- Botox (mid-range): $400 x 3 = $1,200/year
- Letybo (mid-range): $320 x 3 = $960/year
- Potential savings: $240/year (20%)
The New Kid Advantage
Being the newest player in a market dominated by established brands isn't easy. But it comes with advantages that benefit you as a patient.
Why New Can Be Good
Competitive Pricing
New entrants typically price below market leaders to gain share. You benefit from the competition.
Launch Promotions
Providers often offer special pricing when introducing new products. Early adopters can score deals.
Modern Manufacturing
Newer products benefit from advances in production technology and quality control.
Fresh Option
If you haven't loved other neurotoxins, a new formulation gives you another chance to find your match.
The neurotoxin market in the US has been dominated by the same players for years. Letybo adds genuine competition. When companies compete, patients win through better pricing, improved service, and more options.
Availability & Access
Letybo is rolling out across the United States, but availability varies. Not every provider carries it yet. Here's what you need to know about finding it.
Current Status (2025)
- •Available at select medical spas and dermatology practices
- •More providers adding it monthly as distribution expands
- •Major metro areas typically have more options
- •Call ahead to confirm your provider carries Letybo
How to Find a Letybo Provider
- 1. Ask your current injector if they carry or plan to carry Letybo
- 2. Search "Letybo near me" or check Hugel's provider locator
- 3. Call medical spas in your area and ask directly
- 4. Check reviews from early Letybo patients in your region
Switching from Botox to Letybo
Thinking about trying Letybo? The switch is straightforward since both products use the same unit scale.
How to Switch
Wait for Wear-Off
Let your current Botox wear off completely (3-4 months). This gives you a clean slate to evaluate Letybo.
Find a Provider
Locate a practice that carries Letybo. Ask about their experience with it and any current promotions.
Same Dosing
Tell your provider your typical Botox dose. Letybo uses the same units, so 20 units of Botox = 20 units of Letybo.
Evaluate Results
Give it a full treatment cycle. Note how quickly it kicks in, how it looks at peak effect, and how long it lasts.
Good News: No Conversion Math
Unlike switching to Dysport (which requires 2.5-3x more units), switching between Botox and Letybo requires no dosing adjustments. This makes it simple to compare results directly.
What Providers Are Saying
Early feedback from US injectors who've added Letybo to their practice has been generally positive. Here's what they're reporting.
"The 1:1 conversion makes it easy to switch patients over. Results look very similar to Botox. Patients are happy with the lower price point."
Common provider feedback
"I appreciate having another quality option to offer. Some patients prefer trying new products, and this gives them that opportunity with a well-tested formula."
Common provider feedback
Provider Observations
- ✓Onset and duration comparable to Botox
- ✓Smooth, natural-looking results
- ✓Well-tolerated with minimal side effects
- ✓Price point appeals to cost-conscious patients
- ○Limited FDA-approved indications (for now)
The Trust Question: Is It Too New?
Some patients hesitate to try newer products. That's reasonable. But "new to the US" and "new to the world" are different things.
Arguments for Waiting
- •Limited US-specific long-term data
- •Fewer FDA-approved indications
- •No established US rewards program
- •Not all providers carry it yet
Arguments for Trying Now
- •10+ years of use globally
- •FDA approval ensures safety standards
- •Competitive pricing available now
- •Proven in demanding Asian markets
Letybo isn't an experimental product. It's a proven product that's new to this market. The FDA doesn't lower its standards for foreign products. The approval process was just as rigorous as for any other neurotoxin.
The Bottom Line
If you're comfortable with the FDA approval process and intrigued by the potential savings, Letybo is a legitimate option. If you prefer products with decades of US-specific data, Botox remains the gold standard. Neither choice is wrong.
Future Outlook
Letybo's entry into the US market signals growing competition in the neurotoxin space. Here's what to expect going forward.
What's Coming
More FDA Approvals
Hugel will likely seek approval for additional indications (forehead lines, crow's feet) to match Botox's range.
Wider Availability
As distribution expands, more providers will offer Letybo, making it easier to find near you.
Rewards Program
Hugel may launch a loyalty program to compete with Allergan's Alle. This could add value for regular patients.
Price Competition
Letybo's presence puts pressure on other brands to compete on price. This benefits all patients, regardless of which product they choose.
The US neurotoxin market is becoming more competitive. For patients, this means more choices, better pricing, and continued innovation. Whether you try Letybo now or later, its presence benefits you.
Frequently Asked Questions
What is Letybo and how is it different from Botox?
Letybo (letibotulinumtoxinA) is a neurotoxin made by Korean pharmaceutical company Hugel. It received FDA approval in 2024, making it the newest botulinum toxin on the US market. Like Botox, it's botulinum toxin type A, but it's manufactured using a different proprietary process and has been used extensively in Asia for years.
Is Letybo cheaper than Botox?
Early pricing suggests Letybo may be 10-20% less expensive than Botox per unit. As a newer competitor entering an established market, Hugel is positioning Letybo as a cost-effective alternative. However, pricing varies by provider and region, and promotional pricing during the launch period may differ from long-term costs.
Does Letybo use the same units as Botox?
Yes. Letybo uses a 1:1 unit conversion with Botox, unlike Dysport which requires 2.5-3x more units. If you typically get 20 units of Botox, you'd get 20 units of Letybo for the same area. This makes switching and comparing straightforward.
How long does Letybo last compared to Botox?
Letybo lasts about the same as Botox: 3-4 months for most patients. Clinical trials showed similar duration profiles between the two products. Neither has a significant advantage in longevity.
Is Letybo FDA approved?
Yes. Letybo received FDA approval in January 2024 for moderate to severe glabellar lines (frown lines) in adults. It's the first Korean-made neurotoxin to receive FDA approval and the newest botulinum toxin available in the US market.
Has Letybo been tested extensively?
Yes. While new to the US, Letybo has been used in South Korea since 2014 and is approved in over 50 countries. It has a strong track record in Asia with millions of treatments performed. The US FDA approval was based on robust clinical trials meeting the same standards as other neurotoxins.
Can I switch from Botox to Letybo?
Yes, you can switch between them safely. Since they use the same unit scale, the transition is straightforward. Wait until your current Botox wears off, then try Letybo at your next appointment. Many patients experiment with different neurotoxins to find their preference.
Who makes Letybo?
Letybo is manufactured by Hugel, a major South Korean pharmaceutical and aesthetics company founded in 2001. Hugel is one of Asia's largest botulinum toxin producers and has extensive experience in aesthetic medicine. They also make dermal fillers and other cosmetic products.
Is Letybo part of the K-beauty trend?
In a sense, yes. South Korea is known for advanced aesthetic medicine and skincare innovation. Letybo represents Korean pharmaceutical expertise entering the US market. It's been refined through years of use in one of the world's most aesthetics-focused markets.
What areas can Letybo treat?
Currently, Letybo is FDA-approved only for glabellar lines (frown lines between the eyebrows). Off-label use for forehead lines, crow's feet, and other areas is likely as providers gain experience, similar to how other neurotoxins are used.
Are there any unique benefits to Letybo?
Letybo's main advantages are competitive pricing and a fresh option in the market. Some early users report smooth, natural-looking results. As a newer product, providers may offer promotional pricing. It also adds another choice for patients who want alternatives to established brands.
Should I wait for more US data before trying Letybo?
That's a personal choice. While Letybo is new to the US, it has years of real-world use in Asia and strong clinical trial data. If you prefer products with longer US track records, Botox has 20+ years. If you're comfortable with a well-tested product that's simply new to this market, Letybo is a reasonable choice.